摘要
目的:研究PTEN和MDM2在非小细胞肺癌(NSCLC)发生发展中的临床意义。方法:采用免疫组化SP法检测56例非小细胞肺癌组织及20例正常肺组织中PTEN和MDM2蛋白的表达。结果:56例肺癌组织中PTEN表达率为48.21%(27/56),20例正常肺组织中PTEN表达率为95%(19/20),二者有统计学意义(p<0.05)。PTEN表达率与肿瘤的分化程度、临床分期、淋巴结转移有关(p<0.05)。56例肺癌组织中MDM2表达率为53.57%(30/56),20例正常肺组织MDM2表达率为10%(2/20),二者有统计学意义(p<0.05),MDM2表达率与肿瘤的分化程度、临床分期、淋巴结转移有关(p<0.05)。在NSCLC中,PTEN和MDM2的表达呈负相关(p<0.05)。结论:PTEN和MDM2的异常表达在非小细胞肺癌的发生发展过程中起着重要的作用。
Objective： To investigate the expression of PTEN and MDM2 in transitional non-small cell lung cancer（NSCLC）.Methods： The expressions of PTEN and MDM2 were determined by immunohistochemical method in 56 cases of primary lung cancer and 20 case of normal lung tissue.Results： The expression of PTEN in 56 cases of lung carcinoma was 48.21% while which was 95% in 20 cases of normal lung tissues（p0.05）.The expression of PTEN was related to the degree of cell differentiation,clinical stage and lymph node metastasis.The expression of MDM2 in 56 cases of pulmonary carcinoma was 53.57%,while which was10% in 20 cases of normal lung tissues（p0.05）.The expression of MDM2 was related to the degree of tumor cell differentiationclinical stage and lymph node metastasis（p0.05）.There was negative correlation between expression of the PTEN and MDM2 in NSCLC（p0.05）.Conclusion：Abnormal expression of PTEN,MDM2 may play an important role in the malignant progression of NSCLC.
出处
《现代生物医学进展》
CAS
2011年第6期1128-1131,共4页
Progress in Modern Biomedicine
作者简介
作者简介：张红蕊（1984-）女，硕士研究生，研究方向：肺癌的化疗、靶向治疗。电话：15124578218，E—mail：zhanghongrui8412@163．com
通讯作者：王晓红，副教授，硕士研究生导师，主任医师，E—mail：zhanghongrui8412@163.com.
